Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Russell Investments Group Ltd. Raises Stake in Medtronic plc (NYSE:MDT) | news.google.com • |
June 7th Options Now Available For Medtronic | news.google.com • |
MDT (Medtronic) Book Value per Share | news.google.com • |
Medtronic PLC (MDT) Is a Trending Stock: Facts to Know Before Betting on It | zacks.com • |
Medtronic PLC (MDT) Is a Trending Stock: Facts to Know Before Betting on It | news.google.com • |
Medtronic plc (NYSE:MDT) Shares Purchased by Tokio Marine Asset Management Co. Ltd. | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-23 | 2024-04 | 1.45 | N/A | N/A | N/A |
2024-02-20 | 2024-01 | 1.26 | 1.3 | 0.04 | 3.17% |
2023-11-21 | 2023-10 | 1.18 | 1.25 | 0.07 | 5.93% |
2023-08-22 | 2023-07 | 1.11 | 1.2 | 0.09 | 8.11% |
2023-05-25 | 2023-04 | 1.56 | 1.57 | 0.01 | 0.64% |
2023-02-21 | 2023-01 | 1.26 | 1.3 | 0.04 | 3.17% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-22 | Stifel | Upgrade | Buy | Buy |
2023-08-22 | Wells Fargo | Upgrade | Overweight | Overweight |
2023-08-22 | Mizuho | Upgrade | Buy | Buy |
2023-08-22 | UBS | Upgrade | Sell | Sell |
2023-08-22 | Oppenheimer | Upgrade | Perform | Perform |
2023-08-22 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-07-30 | FONG IVAN K | General Counsel | 40.81K | Stock Award(Grant) |
2023-08-02 | KIRK JENNIFER M | Officer | 14.19K | Conversion of Exercise of derivative security |
2024-04-07 | MARINARO MICHAEL | Officer | 27.93K | Sale |
2023-08-02 | MARTHA GEOFFREY S | Chief Executive Officer | 141.14K | Stock Award(Grant) |
2023-08-02 | PARKHILL KAREN L | Chief Financial Officer | 98.72K | Stock Award(Grant) |
2024-02-20 | SALMON SEAN M | Officer | 48.29K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 125.84M | 11.09B | 9.46% |
2023-06-29 | Blackrock Inc. | 114.95M | 10.13B | 8.64% |
2023-06-29 | State Street Corporation | 60.15M | 5.30B | 4.52% |
2023-06-29 | Massachusetts Financial Services Co. | 36.00M | 3.17B | 2.71% |
2023-06-29 | Capital Research Global Investors | 31.49M | 2.77B | 2.37% |
2023-06-29 | Geode Capital Management, LLC | 25.62M | 2.26B | 1.93% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 41.50M | 3.66B | 3.12% |
2023-06-29 | Vanguard 500 Index Fund | 31.68M | 2.79B | 2.38% |
2023-05-30 | Fidelity 500 Index Fund | 14.88M | 1.23B | 1.12% |
2023-08-30 | SPDR S&P 500 ETF Trust | 14.64M | 1.19B | 1.10% |
2023-08-30 | iShares Core S&P 500 ETF | 12.44M | 1.01B | 0.94% |
2023-07-30 | Vanguard Specialized-Dividend Growth Fund | 12.09M | 1.06B | 0.91% |
Dividend | Date |
---|---|
0.69 | 2024-03-22 |
0.69 | 2024-03-21 |
0.69 | 2023-12-20 |
0.69 | 2023-12-19 |
0.69 | 2023-09-21 |
0.69 | 2023-06-22 |
Split | Date |
---|---|
2 : 1 | 1999-09-27 |
2 : 1 | 1997-09-15 |
2 : 1 | 1995-09-29 |
2 : 1 | 1994-09-30 |
2 : 1 | 1991-08-30 |
2 : 1 | 1989-08-31 |
-
-
-
How many knew that Ocugen had a partnership which contractually GUARANTEES them revenues from Covid19 Antibody Testing?
(re: page 22 of annual report):
https://www.sec.gov/Archives/edgar/data/1372299/000110465920053502/tm2017927-1_10ka.htm
Collaboration with Advaite, Inc.
In April 2020, the Company entered into an agreement with Advaite, Inc., (Advaite) to provide certain support services for Advaite's development of a diagnostic test kit that is designed to detect antibodies to COVID-19. ...{Ocugen}... will receive tiered royalty payments based on cumulative net sales of the test kit.The projected market for Covid diagnostic testing is $61B AND GROWING!
MORE IMPORTANTLY Advaite is NOW MOVING on Covid Antibody Testing!
https://www.linkedin.com/mwlite/company/advaite
*The BEAUTY here:
NOBODY KNOWS Ocugen will be collecting potentially BILLION$ in COVID DIAGNOSTICS revenue! They NEVER did a PRESS RELEASE! -
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
-
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT - The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
-
Russell Investments Group Ltd. Raises Stake in Medtronic plc (NYSE:MDT)
news.google.com • -
June 7th Options Now Available For Medtronic
news.google.com • -
MDT (Medtronic) Book Value per Share
news.google.com • -
Medical AI Could Be Your Ticket to Riches: 3 Stocks to Buy
investorplace.com • -
Medtronic (MDT) Laps the Stock Market: Here's Why
news.google.com • -
Medtronic (NYSE:MDT) Stock Price Up 0.4%
news.google.com • -
Medtronic Stock: Buy, Sell, or Hold?
fool.com • -
Cash Burn: 3 Dividend Aristocrats to Dump for Buyback Plays
investorplace.com • -
Medtronic: Dividend Aristocrat Value In Plain Sight
seekingalpha.com • -
35% Undervalued? Medtronic's Future Looks Very Bright
seekingalpha.com • -
7 Dividend Stocks to Buy Now for Decades of Consistent Returns
investorplace.com • -
My Best Dividend Aristocrats For April 2024
seekingalpha.com • -
3 Companies With Strong Irish Operations
fool.com • -
3 Stocks to Buy if the Fed Keeps Rates High for the Rest of 2024
investorplace.com • -
The 3 Most Undervalued Healthcare Stocks to Buy in March 2024
investorplace.com • -
7 Robotic Surgery Stocks to Buy for the Future of Healthcare
investorplace.com • -
Active Rebound: 2 Discrete Semiconductor Stocks Making Moves
marketbeat.com • -
Medtronic is a Dividend Aristocrat That Keeps Gaining
marketbeat.com • -
The Top 3 Healthcare Stocks to Buy in March 2024
investorplace.com • -
What's Next For Medtronic Stock After An Upbeat Q3?
forbes.com • -
Medtronic: Its Recent Beat Proves That It Continues To Be A Rock
seekingalpha.com • -
Where Will Medtronic Stock Be in 3 Years?
fool.com • -
Is Medtronic Stock a Buy Now?
fool.com • -
Why Medtronic Stock Jumped Today
fool.com • -
Medtronic Beats Estimates and Boosts Outlook on Heart, Diabetes Device Sales
investopedia.com • -
Medtronic Is A Healthy Portfolio Boost
seekingalpha.com • -
Medtronic: A Good Choice For Dividend Investors Seeking For Low Volatility
seekingalpha.com • -
February's Smart Buys: 7 Value Stocks You Can't Afford to Miss
investorplace.com • -
7 Dividend Stocks Worth Holding for the Long Haul
investorplace.com • -
Buy, Hold, Profit: 3 Dividend Stocks to Own Forever at Bargain Prices
investorplace.com • -
My Best Dividend Aristocrats For February 2024
seekingalpha.com • -
Top 7 Value Stocks to Outperform Growth in 2024
investorplace.com • -
3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom
investorplace.com • -
3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024
investorplace.com • -
Is Medtronic Stock a Buy Now?
fool.com • -
Value Vault: 3 Forgotten Dividend Aristocrats Offering Steady Income
investorplace.com • -
Medtronic receives FDA approval for deep brain stimulation system
marketbeat.com • -
How To Invest $1 Million In Retirement For Life-Long Income
seekingalpha.com • -
3 Dividend Stocks to Bank On for Consistent Income
investorplace.com • -
Medtronic Stock's Rally Is Set To Continue
seekingalpha.com • -
International Wide-Moat Stocks On Sale - The January 2024 Heat Map
seekingalpha.com •